Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Acronyms CoronavRheum

    • Most Recent Events

    • 25 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2023 Planned End Date changed from 30 Jun 2023 to 30 Apr 2024.
    • 01 Jan 2023 Results evaluating humoral responses to three doses of the inactivated CoronaVac in patients with spondyloarthritis and the effect of therapy, compared with a control group, published in the Joint Bone Spine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top